Cite
109P Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC).
MLA
Laguna, J. C., et al. “109P Subsequent Therapies after Progressing to CDK4/6 Inhibition (CDK4/6i) in Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Advanced Breast Cancer (ABC).” Annals of Oncology, vol. 32, May 2021, pp. S69–70. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.03.123.
APA
Laguna, J. C., Brasó-Maristany, F., Pascual, T., Rodriguez Hernandez, A., Chic, N., Schettini, F., Sanfeliu Torres, E., Gonzalez-Farre, B., Martínez, D., Galván, P., Díez-Guardia, V., Adamo, B., Vidal, M., Guillen Sacoto, M. C., Moreno, R., Prat, A., Muñoz, M., & Martínez-Sáez, O. (2021). 109P Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC). Annals of Oncology, 32, S69–S70. https://doi.org/10.1016/j.annonc.2021.03.123
Chicago
Laguna, J.C., F. Brasó-Maristany, T. Pascual, A. Rodriguez Hernandez, N. Chic, F. Schettini, E. Sanfeliu Torres, et al. 2021. “109P Subsequent Therapies after Progressing to CDK4/6 Inhibition (CDK4/6i) in Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Advanced Breast Cancer (ABC).” Annals of Oncology 32 (May): S69–70. doi:10.1016/j.annonc.2021.03.123.